Mechanical circulatory support in children with cardiac disease  by Duncan, Brian W. et al.
Extracorporeal membrane oxygenation (ECMO) has
been used less frequently for support in adult patients
with cardiac disease. In pediatric patients with cardiac
disease, however, ECMO has been the most commonly
used form of mechanical circulatory support. A major
reason for this is the ready availability of ECMO for the
treatment of neonatal respiratory failure at pediatric
centers. We have successfully used both ECMO and
VAD systems, depending on the clinical situation, to
support pediatric patients with cardiac disease. This
report describes our experience with ECMO and VAD
systems to provide mechanical circulatory support in
children with cardiac disease.
Patients and methods
Patient population, data sources, and statistical analysis.
A retrospective chart review of all patients with a primary
diagnosis of cardiac disease supported with ECMO (67
patients) or a VAD (29 patients) was performed after obtaining
institutional approval. The period of study was from January
M echanical circulatory support after failure of con-ventional medical therapy is now common in
patients with cardiac disease. In adult patients, left ven-
tricular failure due to coronary artery disease has result-
ed in the widespread use of intra-aortic balloon coun-
terpulsation and left ventricular assist devices (LVADs).
The success of long-term support with implantable
LVAD systems has led to their increasing use in the
management of patients with end-stage left ventricular
failure.
Objective: To review the experience from a single center that uses both
extracorporeal membrane oxygenation and ventricular assist devices
for children with cardiac disease requiring mechanical circulatory sup-
port. Methods: A retrospective chart review was performed for all pedi-
atric patients with cardiac disease who required support with extracor-
poreal membrane oxygenation or ventricular assist devices. Statistical
analysis of the impact of multiple clinical parameters on survival was
performed. Results: From 1987 through 1996 we provided mechanical
circulatory support for children with a primary cardiac diagnosis using
extracorporeal membrane oxygenation (67 patients) and ventricular
assist devices (29 patients). Twenty-seven of 67 (40.3%) patients sup-
ported with extracorporeal membrane oxygenation and 12 of 29
(41.4%) patients supported with ventricular assist devices survived to
hospital discharge. Failure of return of ventricular function within 72
hours of the institution of support was an ominous sign in patients sup-
ported with either modality. Univariate analysis revealed the serum pH
at 24 hours of support, the serum bicarbonate at 24 hours of support,
the urine output over the first 24 hours of support, and the development
of renal failure to have a statistically significant association with survival
in children supported with extracorporeal membrane oxygenation.
None of the clinical parameters evaluated by univariate analysis were
significantly associated with survival in the patients supported with ven-
tricular assist devices. Conclusions: Extracorporeal membrane oxygena-
tion and ventricular assist devices represent complementary modalities of
mechanical circulatory support that can both be used effectively in chil-
dren with cardiac disease. (J Thorac Cardiovasc Surg 1999;117:529-42)
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MECHANICAL CIRCULATORY SUPPORT IN CHILDREN WITH CARDIAC DISEASE
1987 through March 1996, comprising the entire experience at
our institution using either modality for mechanical circulatory
support in pediatric patients with cardiac disease.
Multiple clinical variables were analyzed for their impact on
survival to hospital discharge by means of a statistical pro-
gram (JMP Software, SAS Institute, Inc, Cary, NC). Two sets
of variables were evaluated depending on their temporal rela-
tionship to the initiation of circulatory support with either
ECMO or VAD (Appendix: Pre-support and post-support vari-
ables). These clinical variables included demographic factors,
details of cardiopulmonary bypass, hemodynamics before and
after support, ventilatory parameters before and after support,
and details regarding the conduct of support including com-
plications. The impact of continuous variables on the survival
of patients was then assessed with parametric (Student t test)
or nonparametric (Wilcoxon rank sum test) tests of statistical
significance. Categoric variables were assessed with Pearson’s
c
2 test. Pre-support factors with an influence on survival at a
significance level of 0.10 or less were then subjected to multi-
variate analysis by means of a stepwise logistic regression
model. Comparisons of outcomes in terms of cardiac diag-
noses and indications for support for ECMO versus VAD were
performed by Pearson’s c 2 test. Comparisons of complication
rates between ECMO and VAD and the influence of neck can-
nulation or carotid reconstruction on the incidence of neuro-
logic complications in ECMO-supported patients were also
performed with Pearson’s c 2 test.
Components of the ECMO circuit. Techniques that we
used for management of the ECMO circuit have been previ-
ously reported for neonatal and pediatric respiratory sup-
port.1,2 In brief, we used a servoregulated flow system driven
by a roller pump with a membrane oxygenator (Avecor
ECMO Membrane Oxygenator; Avecor Cardiovascular, Inc,
Plymouth, Minn). Pre-membrane and post-membrane in-line
pressure monitors were used. A disposable heat exchanger
was used to maintain constant temperature of blood in the cir-
cuit. The surface area of the oxygenator, based on the patient’s
size, determined priming volumes of the circuit and ranged
from 350 mL (neonates) to 2.5 L (adults). Activated clotting
times were maintained within 180 to 220 seconds by a con-
tinuous heparin infusion and were maintained at lower levels
if significant bleeding occurred on support. Antifibrinolytic
therapy with aminocaproic acid (Amicar; Lederle Parenterals,
Carolina, Puerto Rico) was used in essentially all of these
patients after 1990.1 Aminocaproic acid was initiated as an
intravenous bolus of 100 mg/kg, maintained as a continuous
intravenous infusion of 30 mg/kg per hour for the initial 48
hours of support, and then discontinued.
Cannulation for ECMO. The site of cannulation for
ECMO was based on the discretion of the surgeon, but in
general, patients requiring support in the immediate postop-
erative period had direct transthoracic cannulation of the
aorta and the right atrial appendage. Transthoracic cannula-
tion was especially useful to expedite the institution of sup-
port in patients who had cardiac arrest in the postoperative
period. Peripheral cannulation via the neck or femoral ves-
sels was generally performed in patients who had not had
cardiac surgery or in patients who required ECMO later in
their postoperative course because of concerns about medi-
astinal adhesions. Neck cannulation was performed in
infants and young children, whereas older children and
young adults were often cannulated via the femoral vessels.
Carotid reconstruction was attempted in all cases after neck
cannulation; however, this was not always possible in cases
in which extensive endothelial or full-thickness injury of the
artery had occurred.
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Fig 1. Total patients supported, patients weaned from support, and hospital survivors among the ECMO and VAD
groups.
Components of the VAD circuit. Our entire experience
with VADs used a centrifugal pump system (Bio-Pump;
Medtronic Bio-Medicus, Minneapolis, Minn). For infants and
children less than 10 kg the 50-mL Bio-Pump was used. For
patients above 10 kg the 80-mL Bio-Pump was used. The
priming volume for the 50-mL Bio-Pump and 1⁄4-inch tubing
to complete the circuit was approximately 180 mL. For the 80-
mL Bio-Pump and 3⁄8-inch tubing the priming volume was
approximately 350 mL. After September of 1994 we used can-
nulas and polyvinylchloride tubing coated with the Carmeda
BioActive Surface (Medtronic Corporation, Minneapolis,
Minn) in VAD circuits. The Carmeda BioActive Surface was
not used for ECMO tubing and cannulas. The activated clot-
ting time was maintained at 180 to 200 seconds, and lower
activated clotting times (160-180 seconds) were maintained if
tubing coated with the Carmeda BioActive Surface was used.
Results
General. From January 1987 through March 1996,
67 patients who had a primary diagnosis of cardiac dis-
ease were supported with ECMO and 29 patients with
VAD systems. These patients constituted a diverse
group including cardiac surgical patients who required
support in the preoperative or postoperative period, as
well as cardiac medical patients who did not require
other surgical intervention. Three ECMO-supported
patients required 2 periods of support (runs) for a total
of 70 ECMO runs. One VAD-supported patient
required support with 2 runs and 1 patient required 3
runs, for a total of 32 VAD runs.
The proportions of these patients successfully
weaned from support (ECMO 45/67 [67.2%]; VAD
19/29 [65.5%]) and those who survived to hospital dis-
charge (ECMO 27/67 [40.3%]; VAD 12/29 [41.4%])
were nearly identical for the 2 modes of support (Fig
1). The median age of the ECMO-supported patients
(2.6 months [range 1 day–243 months]) was consider-
ably younger than that of the VAD-supported patients
(20.2 months [range 2 days–280 months]). This was
also reflected in the median weights for the 2 groups
(ECMO 4.3 kg [range 2.4-82 kg] vs VAD 9.0 kg [range
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Fig 2. Age distribution for ECMO- and VAD-supported patients.
2.7-71 kg]). Fig 2 demonstrates the survival by age
group for ECMO and VAD. The median duration of
support was longer for the ECMO-supported patients
(4.8 days [range 0-29 days]) than for the VAD-support-
ed patients (1.8 days [range 0-7.8 days]).
Over this 10-year period the number of patients
undergoing mechanical circulatory support increased,
with a plateau over the last 2 to 3 years (Fig 3). With
1995 as the last complete year of study, 16 children
required mechanical support (11 ECMO, 5 VAD) with
10 survivors (63%; 7 ECMO, 3 VAD). Less than 1% of
all cardiac surgical cases required mechanical circula-
tory support with either ECMO or VAD during the peri-
od of study.
Modes of support. Sixty-four of the 70 ECMO runs
used venoarterial support, whereas 6 of the runs used
venovenous support. For the 32 VAD runs there were
24 left ventricular assist device (LVAD) runs, 6 right
ventricular assist device (RVAD) runs, and 2 biven-
tricular assist device (BVAD) runs. Four patients
treated with a VAD required conversion to ECMO for
oxygenator support, with 1 (25%) survivor. No patients
treated by ECMO were converted to VAD after satis-
factory institution of support. One patient was initially
supported with intra-aortic balloon counterpulsation
before the institution of ECMO and did not survive.
Cardiac diagnoses and indications for support.
The survival according to cardiac diagnoses (Table I)
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Fig 3. Annual survival for ECMO- and VAD-supported patients throughout the period of study.
and the indications for support (Table II) are as listed.
The number of runs in Table II exceeds the number of
patients in Table I because of the multiple periods of
support in the 3 ECMO- and 2 VAD-supported children
discussed earlier. As seen in Table II, a significant num-
ber of ECMO-supported patients required support for
hypoxemia (25/70 [35.7%]), which included a large
number of children requiring support for pulmonary
disease (pneumonia, pulmonary hemorrhage) irrespec-
tive of their cardiac disease. The indication for support
was for cardiac arrest in 17 of 70 (24.3%) ECMO runs
and 5 of 32 (15.6%) VAD runs. The survival for this
critically ill subset of patients (7/17 [41%] ECMO sur-
vivors; 2/5 [40%] VAD survivors) was equivalent to the
survival for all other indications for each modality
(ECMO 20/53 [38%], VAD 10/27 [37%]). Three of the
7 ECMO-treated patients and 1 of the 2 VAD-treated
patients surviving after pre-support cardiac arrest had
cardiopulmonary resuscitation for more than 1 hour
before the institution of support. Statistical analysis
comparing outcomes in terms of underlying cardiac
diagnosis or indications for support was performed for
ECMO versus VAD. There was no difference in out-
come for ECMO- or VAD-supported patients when
analyzed for a given diagnostic group or specific indi-
cation for support (data not shown).
Univariate analysis of survival factors
ECMO. Table III lists those clinical parameters, from
the original list that was analyzed (Appendix), found to
have a P value of .10 or less in a univariate analysis of
survival. None of the pre-support variables attained a
.05 level of statistical significance for all 67 ECMO-
supported patients. Post-support variables attaining a P
value of .05 or less for all 67 ECMO-supported patients
included the serum pH at 24 hours of support, serum
bicarbonate at 24 hours of support, the development of
severe renal failure (creatinine > 3.0 mg/dL or dialysis),
and the urine output over the first 24 hours of support.
The lowest pH at 24 hours of support for any survivor
was 7.38 and the lowest serum bicarbonate at 24 hours
of support for survivors was 22 mmol/dL. Univariate
analysis was then repeated for the same pre-support and
post-support variables for the subset of 56 patients who
required ECMO in the perioperative period of cardiac
surgery. For this group of patients, failure to wean from
cardiopulmonary bypass attained a .05 level of statisti-
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Table I. ECMO and VAD: Diagnostic groups and survival
ECMO VAD
Diagnosis Survivors Nonsurvivors Total Survivors Nonsurvivors Total
Left-to-right shunt 1 (14.3%) 6 (85.7%) 7 0 1 (100%) 1
Left-sided obstruction 5 (41.7%) 7 (58.3%) 12 1 (25%) 3 (75%) 4
Right-sided obstruction 1 (100%) 0 1 0 2 (100%) 2
Cyanosis, › PBF 8 (36.4%) 14 (63.6%) 22 1 (25%) 3 (75%) 4
Cyanosis, fl PBF 7 (41.2%) 10 (58.8%) 17 1 (50%) 1 (50%) 2
ALCAPA 1 (100%) 0 1 5 (71.4%) 2 (28.6%) 7
Cardiomyopathy 3 (75%) 1 (25%) 4 3 (60%) 2 (40%) 5
Other 1 (33.3%) 2 (66.7%) 3 1 (25%) 3 (75%) 4
Total 27 (40.3%) 40 (59.7%) 67 12 (41.4%) 17 (58.6%) 29
ALCAPA, Anomalous left coronary artery from pulmonary artery; PBF, Pulmonary blood flow.
Table II. ECMO and VAD: Indications for support and survival
ECMO VAD
Indication Survivors Nonsurvivors Total Survivors Nonsurvivors Total
Hypoxia 11 (44%) 14 (56%) 25 — — —
Preop. cardiac failure 1 (100%) 0 1 — — —
Postop. cardiac failure 2 (28.6%) 5 (71.4%) 7 0 2 (100%) 2
Cardiac arrest 7 (41.2%) 10 (58.8%) 17 2 (40%) 3 (60%) 5
Bridge to transplantation 2 (67%) 1 (33%) 3 2 (50%) 2 (50%) 4
Failure to wean from CPB 1 (10%) 9 (90%) 10 7 (36.8%) 12 (63.2%) 19
PHT 1 (25%) 3 (75%) 4 — — —
Failure, no operation 2 (67%) 1 (33%) 3 1 (50%) 1 (50%) 2
Totals 27 (38.6%) 43 (61.4%) 70 12 (37.5%) 20 (62.5%) 32
CPB, Cardiopulmonary bypass; PHT, pulmonary hypertension.
cal significance. Significant post-support factors includ-
ed the serum pH at 24 hours of support, serum bicar-
bonate at 24 hours of support, dopamine dose at 24
hours of support, estimated blood loss during support,
and the epinephrine dose at 24 hours of support.
VAD. None of the pre-support or post-support clinical
parameters tested attained statistical significance at the
.05 level for all 29 VAD-supported patients. Repeating
the univariate analysis for pre-support variables for the
27 patients requiring support in the perioperative peri-
od of cardiac surgery revealed the use of hypothermic
circulatory arrest during the cardiac operation, the
diagnosis of anomalous left coronary artery from the
pulmonary artery (ALCAPA), and the nature of the
operative procedure (palliative or a totally corrective
operation) to have a trend toward statistical signifi-
cance (Table III). Univariate analysis of the post-sup-
port variables for the 27 VAD patients who were sup-
ported during the perioperative period of cardiac
surgery revealed the central venous pressure at 24
hours of support to have a statistically significant
impact on survival.
Multivariate analysis of survival factors. Pre-sup-
port factors that had a .10 or smaller P value for all
patients supported with ECMO or VAD were then ana-
lyzed with a multivariate model by means of stepwise
logistic regression. Multivariate analysis was also per-
formed on pre-support factors with a .10 level of statis-
tical significance by univariate analysis for patients
supported with either ECMO or VAD in the periopera-
tive period. No combination of factors attained a .05
significance level with these analyses.
Transplantation experience. The patterns of use of
mechanical circulatory support and outcomes for
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Table III. Univariate analysis of survival of patients supported by ECMO or VAD
Parameter Survivors Nonsurvivors P value
Total ECMO
Pre-support variable
Left atrial pressure (mm Hg) 15.0 ± 5.5 23.1 ± 9.4 .058
Post-support variables
pH at 24 h 7.51 ± 0.07 7.44 ± 0.08 .003
tCO2 at 24 h (mmol/dL) 31.5 ± 4.7 27.1 ± 6.8 .007
Renal failure 2/27 (7.4%) 13/40 (32.5%) .016
Urine output in first 24 h (mL/kg/h) 3.2 (range 0.32-9.1) 1.85 (range 0-9.9) .047
Epinephrine at 24 h (m g/kg/min) 0 0.024 ± 0.10 .054
EBL (mL/kg) 62.2 (range 0-704) 115.2 (range 0-1555) .060
Dopamine at 24 h (m g/kg/min) 3.0 ± 3.6 4.9 ± 4.8 .077
Perioperative ECMO
Pre-support variables
Failure to wean from CPB 1/10 (10%) 9/10 (90%) .030
Left atrial pressure (mm Hg) 15.0 ± 5.5 23.1 ± 9.4 .058
Post-support variables
pH at 24 h 7.51 ± 0.06 7.45 ± 0.08 .003
tCO2 at 24 h (mmol/dL) 32.0 ± 4.4 27.1 ± 6.3 .003
Dopamine at 24 h (m g/kg/min) 2.4 ± 2.4 5.5 ± 5.1 .015
EBL during support (mL/kg) 98.5 (range 0-704) 161.0 (range 0-1555) .023
Epinephrine at 24 h (m g/kg/min) 0 0.03 ± 0.1 .043
Urine output in first 24 h (mL/kg/h) 3.1 (range 0.3-9.1) 1.73 (range 0-9.9) .051
Total VAD
Pre-support variable
ALCAPA 5/7 (71%) 2/7 (29%) .064
Post-support variable
None
Perioperative VAD
Pre-support variables
HCA in OR 1/11 (9.1%) 10/11 (91%) .053
ALCAPA 5/7 (71%) 2/7 (29%) .055
Palliative/corrective operation 0/4 4/4 (100%) .072
Post-support variable
CVP at 24 h (mm Hg) 12.0 ± 1.7 19.3 ± 4.2 .04
tCO2, Serum bicarbonate; EBL, estimated blood loss; CPB, cardiopulmonary bypass; ALCAPA, anomalous left coronary artery from the pulmonary artery; HCA,
hypothermic circulatory arrest; OR, operating room; CVP, central venous pressure.
patients undergoing cardiac transplantation are listed in
Table IV. Five patients were successfully supported with
ECMO (2 patients) or VAD (3 patients) as a bridge to
transplantation. Four of these patients survived to hospi-
tal discharge, whereas a single VAD-supported patient
died after cardiac transplantation. In 2 patients attempt-
ed bridging to transplantation was unsuccessful (1
ECMO, 1 VAD), that is, support was initiated in antici-
pation of transplantation but was discontinued because
of complications before a donor organ became available. 
Complications. Table V compares the relative rates
of complications by organ system for ECMO and VAD.
For this analysis, the occurrence of a given complica-
tion was determined for each individual ECMO (n =
70) or VAD run (n = 32). Gastrointestinal and neuro-
logic complications were seen more frequently in
ECMO runs than in VAD runs. Mechanical complica-
tions related to the circuit tended to be more common
for ECMO than for VAD support. No complications
were more frequent with VAD support.
Table VI lists the neurologic complications in these
children. Intracranial hemorrhage and seizures were
seen most frequently during ECMO support, whereas
anoxic encephalopathy was seen in 3 of the 4 neurolog-
ic complications occurring in VAD-supported children.
Table VII demonstrates that neither neck cannulation
nor carotid reconstruction had any impact on the occur-
rence of neurologic complications with ECMO support.
Causes of death. Ventricular failure and multiple
system organ failure were the most common causes of
death for both ECMO- and VAD-supported patients
(Table VIII).
Influence of length of time to recovery of ventric-
ular function on survival. We examined the rate of
return of ventricular function for survivors who did not
undergo transplantation compared with those patients
who were unable to be weaned from support (nonsur-
vivors and survivors who required cardiac transplanta-
tion) (Fig 4). Return of ventricular function was
defined as the return of a pulsatile waveform on the
peripheral arterial trace on maximal levels of support
(80% of normal cardiac output provided by the device).
Twenty-four of 25 (96%) ECMO survivors who did not
undergo transplantation had return of a pulsatile wave-
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Table IV. Transplantation experience
Survivors Diagnosis Nonsurvivors Diagnosis
ECMO
Successful bridge 2 2 (myocarditis) 0
Unsuccessful bridge — — 1 1 (cardiomyopathy)
Post-transplantation support 0 0
Total ECMO patients 2 (66%) 1 (33%)
VAD
Successful bridge 2 1 (myocarditis), 1 1 (myocarditis)
1 (postcardiotomy)
Unsuccessful bridge — — 1 1 (myocarditis)
Post-transplantation support 1 1 (myocarditis) 1 1 (postcardiotomy)
Total VAD patients 3 (50%) 3 (50%)
Total patients = 9 5 (56%) 4 (44%)
Table V. Comparison of complication rates for ECMO and VAD runs
Complication ECMO incidence VAD incidence P value
Hemorrhage 28/70 (40.0%) 14/32 (43.8%) .72
Central nervous system 22/70 (31.4%) 4/32 (12.5%) .042
Cardiovascular 26/70 (37.1%) 13/32 (40.6%) .74
Pulmonary 15/70 (21.4%) 4/32 (12.5%) .28
Gastrointestinal 17/70 (24.3%) 1/32 (3.1%) .009
Mechanical 18/70 (25.7%) 3/32 (9.4%) .058
Renal failure 15/70 (21.4%) 3/32 (9.4%) .14
(dialysis or serum creatinine ‡ 3.0)
Any severe infection 19/70 (27.1%) 10/32 (31.3%) .67
Mediastinitis 3/70 (4.3%) 2/32 (6.3%) .67
Pneumonia 10/70 (14.3%) 1/32 (3.1%) .092
Positive blood cultures 9/70 (12.9%) 4/32 (12.5%) .96
form at maximal levels of support by 72 hours of sup-
port. All surviving patients in the VAD group had return
of ventricular function within 48 hours of the initiation
of support, whereas patients in whom ejection had not
returned after this point died or required cardiac trans-
plantation.
Discussion 
Several recent reports have been published concern-
ing series in which either ECMO or VAD was used for
the support of pediatric patients with cardiac dis-
ease.3-10 This report details our 10-year experience with
both ECMO and VAD in children with cardiac disease
as a summary of this experience and as an attempt to
provide a comparison of these two modalities. These
two modes of support demonstrated nearly identical
rates of weaning from support and survival, suggesting
that both may be used effectively and complement each
other in the treatment of these children.
Cardiac diagnoses. Examining the underlying diag-
noses of these patients demonstrates that the appropri-
ate use of ECMO or VAD is based on considerations
regarding the specific anatomy and physiology present
in a given case. Cyanotic heart disease was present in
more than half of the children who were supported with
ECMO. The most common diagnoses in the VAD-sup-
ported patients were predominant univentricular failure
such as ALCAPA or cardiomyopathy. We believe that
ECMO is superior to VAD for the support of most chil-
dren with complex congenital heart disease such as
cyanotic lesions in which hypoxia, pulmonary hyper-
tension, or biventricular failure contributes to the
pathophysiology necessitating mechanical circulatory
support. ECMO provides greater flexibility than VAD
in these instances. In lesions in which univentricular
failure predominates, such as ALCAPA, VAD provides
an effective approach.11 These considerations are gen-
erally true, but we and others have successfully used
VAD to support newborn infants with complex cyanot-
ic lesions when univentricular failure predominates.9,10
Indications for support. Examination of the indica-
tions for support demonstrates the high incidence of
hypoxia and pulmonary hypertension in the ECMO-
treated patients. ECMO was required in several of
these patients despite the use of high-frequency venti-
lation, nitric oxide, and liquid ventilation. These mea-
sures have been reported to decrease the need for
ECMO when used to treat neonatal and pediatric respi-
ratory failure.12.13 Our experience indicates that these
adjunctive respiratory measures may fail when severe
hypoxia occurs in the setting of congenital heart dis-
ease, with many of these children still ultimately re-
quiring ECMO support.
The survival for patients who required ECMO or
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Table VI. Type and number of neurologic complications
occurring during ECMO and VAD runs
No. of runs 
CNS complication (% of total CNS complications)
ECMO
Cerebral infarction 4 (18.2%)
Intracranial hemorrhage 8 (36.4%)
Seizures 5 (22.7%)
Developmental delay 1 (4.6%)
Horner’s syndrome 1 (4.6%)
Abnormal EEG 1 (4.6%)
Anoxic encephalopathy 2 (9.2%)
Total 22
VAD
Anoxic encephalopathy 3 (75%)
Prolonged muscle weakness 1 (25%)
Total 4
CNS, Central nervous system; EEG, electroencephalogram.
Table VII. Influence of neck cannulation and carotid
reconstruction on incidence of neurologic complications
in ECMO-supported patients
CNS 
complications P value
Neck cannulation .40
With neck cannulation 16/46 (34.8%)
Without neck cannulation 6/24 (25.0%)
Carotid reconstruction .72
With carotid reconstruction 3/10 (30%)
Without carotid reconstruction 13/26 (36.1%)
CNS, Central nervous system.
Table VIII. ECMO and VAD causes of death
ECMO VAD
Cause of death No. % No. %
Ventricular failure 14 35 9 53
Multiple system organ failure 12 30 4 23
Respiratory failure 4 10 — —
Anoxic brain injury 2 5 2 12
Intracranial hemorrhage 2 5 — —
Arrhythmia 2 5 1 6
Inadequate flow rates 2 5 — —
due to poor drainage
Aortic cannula dislodgment 1 2.5 — —
Hemorrhage (torn umbilical vein) 1 2.5 — —
Hemorrhage (mediastinal) — — 1 6
Total 40 100% 17 100%
VAD support after having a cardiac arrest was nearly
identical to the survival for all other indications. These
results are in agreement with earlier reports that
demonstrate survival of 25% to 65% after cardiac arrest
in these patients with good long-term functional sta-
tus.14,15 In the surviving patients rescued with ECMO,
there was no higher complication rate for any organ
system. Importantly, the incidence of neurologic com-
plications was no different from that in other survivors
(data not shown).
Contraindications for support. We have not devel-
oped rigid contraindications for mechanical support but
evaluate each case individually. Severe dysfunction of
other organ systems (especially central nervous sys-
tem) before initiation of support and extreme prematu-
rity represent situations in which support would not be
offered. We have successfully supported patients with a
shunted single ventricle, patients with pre-support car-
diac arrest, patients undergoing palliative cardiac oper-
ations, and patients with coexisting congenital
diaphragmatic hernia. None of these represent absolute
contraindications for support in our experience.
Determinants of survival. Determinants of the ade-
quacy of perfusion within the first 24 hours of support
as determined by the pH, serum bicarbonate, and urine
output had prognostic significance in the ECMO group.
We had no survivors with a pH below 7.38 or a serum
bicarbonate below 22 mmol/dL at 24 hours of support.
Inasmuch as cardiac output was presumably normal-
ized by the institution of support, abnormal values for
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Fig 4. Time to return of ventricular function versus survival for ECMO- and VAD-supported patients. 
these variables measured at this early point probably
reflected the impact of significant hypoperfusion in the
period before the institution of ECMO, rather than
ongoing systemic hypoperfusion. The requirement of
significant pressor support, with dopamine or epineph-
rine, to maintain perfusion during perioperative ECMO
carried a poor prognosis.
Patients requiring ECMO support for failure to wean
from cardiopulmonary bypass had a 90% mortality
rate. Although not a statistically significant improve-
ment in outcome, VAD-supported patients who could
not be weaned from cardiopulmonary bypass fared
somewhat better, with 7 survivors of 19 total patients
(37%). A major difference in these 2 groups was due to
the influence of the LVAD-supported patients with
ALCAPA, many of whom cannot be weaned from car-
diopulmonary bypass, yet have an overall good outlook
with mechanical circulatory support.11 The predomi-
nance of younger patients with complex cyanotic
lesions was largely responsible for the poorer outcome
of patients with ECMO support instituted in the operat-
ing room. Failure to wean from cardiopulmonary
bypass is not a contraindication for ECMO support, but
its use in younger patients with complex anatomy
should be selective in this setting because of an appre-
ciation of the poor outlook for this group.
Conclusions were more difficult to draw in the VAD-
supported group because of their smaller numbers;
however, right-sided filling pressures on support, the
use of circulatory arrest during the cardiac operation,
and the curative or palliative nature of the cardiac repair
were important clinical parameters for outcome in
patients supported in the perioperative period. Right
ventricular failure manifest by an elevated central
venous pressure in LVAD-supported patients should
suggest the need for ECMO or BVAD. The need for
hypothermic circulatory arrest for operative repair
implies a complex procedure on a newborn patient. As
previously discussed, newborn patients with complex
heart disease are often best supported with ECMO.
Complications. Although hemorrhagic complica-
tions were the most common complication in both
groups, excessive blood loss was a statistically signifi-
cant risk factor for death only in the ECMO-supported
patients. Risk factors for excessive bleeding in our
patients included chest cannulation and the need for
support in the operating room (data not shown). We
have previously described the use of aminocaproic acid
to control bleeding while on ECMO,1 which we also
use for VAD-supported patients. We have used apro-
tinin and tranexamic acid only sporadically.
Considered by organ system, only renal failure in
ECMO-supported patients had a significant negative
impact on survival. Neurologic complications were
more common during ECMO support than during VAD
support. Neurologic complications were not associated
with higher mortality in these patients but obviously
represent a source of great morbidity. Much of the
increased incidence of neurologic complications in the
ECMO-supported patients can be attributed to higher
rates of intracranial hemorrhage. This higher incidence
of intracranial bleeding reflects the younger age of the
ECMO-supported patients, including a large number of
newborn infants in addition to the higher levels of anti-
coagulation required for the ECMO circuit. The higher
incidence of central nervous system complications was
independent of carotid cannulation or reconstruction.
The relatively higher rate of mechanical complica-
tions in the ECMO group is due to the increased com-
plexity of the circuit. The presence of the oxygenator
itself is a significant source of morbidity resulting in
trauma to blood elements and activation of systemic
inflammatory and coagulation cascades. In addition,
multiple connector sites required in the ECMO circuit
increase the risk of air and particulate embolism, and
oxygenator failure requires interruption of flow and
replacement. Complications related to the circuit were
not associated with a significantly higher mortality.
Survival and length of time until return of ventric-
ular function. We observed that ventricular function
returned early after the institution of support in sur-
vivors who did not require transplantation. Lack of
return of ventricular function within 48 to 72 hours was
an ominous sign in our experience. We have used these
results as additional prognostic data for these children.
Patients without return of ventricular function within 48
to 72 hours of support are currently considered for
transplantation or termination of support if there are
contraindications to transplantation. Delaying this deci-
sion while awaiting return of ventricular function
beyond the first 48 to 72 hours of support is not justified
according to our data. Because of the scarcity of organ
donors in the pediatric population, early consideration
for transplantation optimizes the chances of successful
organ procurement. Over this 10-year period only seven
patients were supported with ECMO or VAD in an
attempt to bridge them to transplantation, with five
patients having successful transplantation. Our current
practice of listing these children for transplantation
when ventricular function has not returned after 48 to 72
hours may increase the number of patients who are suc-
cessfully bridged to transplantation.
Cardiac failure and multiple system organ failure were
the major causes of death in both ECMO- and VAD-sup-
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ported patients. For both of these conditions, early and
aggressive consideration for transplantation may lead to
higher salvage rates. We have maintained patients for as
long as 4 weeks with mechanical circulatory support;
however, the development of infectious complications
and multiple system organ failure eventually supervenes.
The use of pulsatile circulatory perfusion devices for
long-term support in children may delay the develop-
ment of this process. Although no pulsatile flow systems
are currently available in the United States for chronic
pediatric circulatory support, the development of such
devices will be a welcome addition to the therapeutic
options for these critically ill children.
Selection of the appropriate modality of support:
ECMO versus VAD. Table IX is a “scorecard” reflect-
ing the relative advantages and disadvantages of
ECMO and VAD in the treatment of pediatric patients
with cardiac disease. These general points may aid in
selecting the appropriate mode of support in a given
clinical setting. Pediatric centers have extensive experi-
ence with ECMO for the treatment of neonatal respira-
tory failure where expansion of its use to include
patients with cardiac disease is often easily accom-
plished. Because of the absence of an oxygenator, VAD
circuits are simpler, require less anticoagulation, and
result in less blood trauma. ECMO may be instituted
peripherally with neck or groin cannulation, whereas
VAD requires a sternotomy. Left ventricular decom-
pression is effectively performed by LVAD or BVAD;
in patients supported with ECMO, the occurrence of
left ventricular distention requires aggressive monitor-
ing and prompt treatment with left atrial venting or bal-
loon atrial septostomy. ALCAPA is the paradigm lesion
successfully supported with LVAD, whereas ECMO
provides greater flexibility in dealing with some forms
of complex congenital heart disease in which pul-
monary hypertension and hypoxia contribute signifi-
cantly to the pathophysiology. Finally, biventricular
support is easier to institute with ECMO, which
requires only 2 cannulation sites compared with 4 can-
nulation sites required for BVAD. Because of size con-
straints, this is an important consideration when biven-
tricular support is required in neonates.
Summary 
ECMO and VAD represent complementary modalities
to provide mechanical circulatory support in children
with cardiac disease in whom conventional medical
forms of management have failed. The two modalities
are equally efficacious when used for the appropriate
diagnosis and indication. ECMO was most often useful
for complex congenital cardiac lesions, whereas ALCA-
PA represents the paradigm lesion for LVAD support in
children. Early indicators of the adequacy of perfusion
during support, blood loss during support, and the
development of renal failure had a significant impact on
survival in ECMO-supported patients. Hemorrhage was
the most frequent complication for both modalities of
support. Neurologic complications were seen more fre-
quently in ECMO- as opposed to VAD-supported
patients. We advocate early consideration for transplan-
tation in patients in whom ventricular function does not
recover within 48 to 72 hours after the institution of
support. Because of the scarcity of organ donors in the
pediatric population, early listing for transplantation
optimizes the chances of successful organ procurement.
Earlier consideration for transplantation should have a
significant impact on the most common causes of death
in these patients, namely, cardiac failure and multiple
system organ failure.
We thank Kimberlee Gauvreau, ScD, for her invaluable
assistance in the statistical analysis of these data.
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Table IX. Score card for appropriate modality of sup-
port: ECMO versus VAD
ECMO VAD
Experience in pediatric centers 3
Simplicity of circuit 3
Peripheral cannulation 3
Left ventricular decompression 3
ALCAPA 3
Treatment of pulmonary hypertension 3
and hypoxia
Biventricular support in neonates 3
ALCAPA, Anomalous left coronary artery from the pulmonary artery.
cardiac rescue in children with severe myocardial dysfunction.
Crit Card Med 1993;21:1020-8.
6. Meliones JN, Custer JR, Snedecor S, Moler FW, O’Rourke P,
Delius RE. Extracorporeal life support for cardiac assist in pedi-
atric patients. Circulation 1991;84(Suppl):III168-72.
7. Raithel SC, Pennington DG, Boegner E, Fiore A, Weber TR.
Extracorporeal membrane oxygenation in children after cardiac
surgery. Circulation 1992;86(Suppl):II305-10.
8. Weinhaus L, Canter C, Noetzel M, McAlister W, Spray TL.
Extracorporeal membrane oxygenation for circulatory support
after repair of congenital heart defects. Ann Thorac Surg 1989;
48:206-12.
9. Karl TR, Sano S, Horton S, Mee RBB. Centrifugal pump left
heart assist in pediatric cardiac operations. J Thorac Cardiovasc
Surg 1991;102:624-30.
10. Karl TR. Extracorporeal circulatory support in infants and chil-
dren. Semin Thorac Cardiovasc Surg 1994;6:154-60.
11. del Nido PJ, Duncan BW, Mayer JE Jr, Wessel DL, LaPierre RL,
Jonas RA. Left ventricular assist device significantly improves
survival in children with anomalous left coronary artery and left
ventricular dysfunction. Ann Thorac Surg. In press.
12. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric
oxide in full-term and nearly full-term infants with hypoxic res-
piratory failure. N Engl J Med 1997;336:597-604.
13. Roberts JD, Fineman JR, Morin FC, Shaul PW, Rimar S,
Schreiber MD, et al. Inhaled nitric oxide and persistent pul-
monary hypertension of the newborn. N Engl J Med 1997;336:
605-10.
14. del Nido PJ, Armitage JM, Fricker FJ, Shaver M, Cipriani L,
Dayal G, et al. Extracorporeal membrane oxygenation support as
a bridge to pediatric heart transplantation. Circulation 1994;90(Pt
2):II66-9.
15. Dembitsky WP, Moreno-Cabral RJ, Adamson RM, Daily PO.
Emergency resuscitation using portable extracorporeal membrane
oxygenation. Ann Thorac Surg 1993;55:304-9.
Appendix: Clinical parameters evaluated for
impact on survival
Pre-support variables
Demographics:
Sex
Weight
Age
Intraoperative features:
Cardiopulmonary bypass time
Aortic crossclamp time
Circulatory arrest time
Hemodynamics before initiation of support:
Central venous pressure
Right atrial pressure
Left atrial pressure
Systolic blood pressure
Diastolic blood pressure
Mean arterial blood pressure
Arterial blood gases before initiation of support:
Oxygen tension
Carbon dioxide tension
pH
Serum bicarbonate
Mixed venous oxygen saturation
Ventilator settings before initiation of support:
Inspired oxygen fraction
Peak inspiratory pressure
Positive end-expiratory pressure
Tidal volume
Ventilatory rate
Inotropic doses before initiation of support:
Dopamine
Amrinone
Dobutamine
Epinephrine
Site of cannulation:
Neck
Chest
Groin
Miscellaneous:
Urine output before support
High-frequency ventilation
Liquid ventilation
Use of nitric oxide
Pre-support cardiopulmonary resuscitation
Duration of cardiopulmonary resuscitation
Residual lesions
Palliative versus corrective operation
Post-support variables
Hemodynamics at 24 hours of support:
Central venous pressure
Right atrial pressure
Left atrial pressure
Systolic blood pressure
Diastolic blood pressure
Mean arterial blood pressure
Arterial blood gases at 24 hours of support:
Oxygen tension
Carbon dioxide tension
pH
Serum bicarbonate
Mixed venous oxygen saturation
Ventilator settings at 24 hours of support:
Inspired oxygen fraction
Peak inspiratory pressure
Positive end-expiratory pressure
Tidal volume
Ventilatory rate
Blood product transfusions during support:
Packed red blood cells
Whole blood
Fresh frozen plasma
Cryoprecipitate
Estimated blood loss on support
Number of re-explorations for bleeding
Use of aminocaproic acid
Inotropic doses at 24 hours of support:
Dopamine
540 Duncan et al The Journal of Thoracic and
Cardiovascular Surgery
March 1999
Amrinone
Dobutamine
Epinephrine
Complication by organ system:
Cardiovascular
Pulmonary
Gastrointestinal
Renal
Infectious
Hemorrhagic
Mechanical
Miscellaneous:
Urine output (over the first 24 hours of support)
Reoperation for residual lesions
Duration chest open
Duration intubated
Carotid reconstruction
Commentary 
Although there is a large experience worldwide with
the VAD in adults, and a proliferation of effective sup-
port systems, the pediatric experience remains relative-
ly limited. This is due to size and technical considera-
tions, but also to a perception that patients with
complex congenital heart disease are unsuitable for
univentricular support. Duncan and associates have
provided evidence to the contrary, reporting their large
pediatric experience with VAD and ECMO for cardiac
and cardiopulmonary support. The clinical questions
addressed are important for pediatric surgeons. The
time frame and the similarities in patient populations
and outcome invite commentary and comparison with
experience at the Royal Children’s Hospital.
Since 1989, we have been using both VAD and
ECMO,1-4 always employing centrifugal pumps. The
centrifugal-pump VAD circuit is straightforward in
concept and design, can be rapidly assembled and
primed, and requires little technical attention. It is suit-
able for many cardiac arrest situations. In this format,
the centrifugal pump is responsive to changes in the
peripheral circulation, allowing fine tuning of inotrop-
ic drugs and vasodilators before weaning. The centrifu-
gal pump is probably safer than a roller pump for long-
term support outside the operating theater, since it
generates constant pressure rather than flow.
The majority of our postoperative support has been
with VAD rather than ECMO systems. In practice, at
least for intraoperative placement, adequacy of univen-
tricular support can be assessed by converting car-
diopulmonary bypass to partial left heart assist, and
ceasing gas exchange across the oxygenator. The
bypass circuit can then be converted to centrifugal-
pump VAD or ECMO, as appropriate, on the basis of
hemodynamics, oxygenation and carbon dioxide clear-
ance, and acid base status.
We have used the VAD in 53 patients, median age 3.5
months (range 2 days–19 years) and median weight 4
kg (range 1.9-70 kg). Our results3-5 were remarkably
similar to those of Duncan and colleagues. The time on
VAD was similar for survivors and nonsurvivors (P =
.69), with a median of 75 hours. Thirty-eight of 53 chil-
dren were weaned from VAD (.72, CL = .57-.83) and
24 of 53 were eventually discharged (.46, CL = .31-
.61). Kaplan-Meier survival probability at 1 year was
.44 (CL = .31-.58). The post-weaning deaths reflected
continued cardiac problems rather than specific VAD-
related complications. Age, weight, support time, car-
diopulmonary bypass time, ischemic time, univentricu-
lar anatomy, and timing of placement (intraoperative
versus postoperative) were not strongly associated with
survival probability. By comparison, of 40 patients sup-
ported with ECMO, 19 were weaned, 3 bridged to
transplantation, and 19 eventually discharged from the
hospital. Thus, although the weaning probability was
better with VAD (.71 vs .48, P = .014), as in Boston the
discharge probability was similar (.46 vs .48, P = 1.0).
In interpreting these results, one must consider that
most of the patients treated with a VAD could have
been supported with ECMO, but the reverse would not
generally apply.
In the Boston experience, younger patients were
more likely to be supported with ECMO than with
VAD, because of the complexity of the underlying
heart disease and technical considerations. In our own
practice, 38 of 53 patients supported with a VAD
weighed less than 6 kg.6 The probability of weaning
was similar to that for the older patients (P = .07), but
the 1-year survival probability was poorer, primarily
related to irreversible cardiac disease. The smallest
patient in our series was a 19-day-old, 1.9-kg baby with
Taussig-Bing anomaly and arch obstruction, who was
placed on VAD support in the postoperative period dur-
ing a prolonged (1 hour) cardiac arrest and survived
with no neurologic sequelae. As would be the case in
Boston, we have been obliged to redefine the upper
limit for reasonable resuscitation time in children in the
era of circulatory support.
Neither VAD nor ECMO in this format is eminently
suitable for long-term support. Our longest successful
supports have been 120 hours (ECMO) and 144 hours
(VAD), although nonsurvivors were well supported
metabolically for 384 hours (ECMO) and 428 hours
(VAD). Our longest ECMO support for noncardiac
indications has been 6 weeks. The usefulness of cen-
trifugal-pump VAD and ECMO as a bridge to trans-
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plantation will depend heavily on the immediate avail-
ability of suitable donor hearts, a major problem in
many parts of the world. A major limitation is our
inability to wean most patients from ventilatory support
during centrifugal-pump VAD and ECMO, mobilize
them, and make them independent of the intensive care
unit.
There are two important questions to be addressed in
analyzing this experience. First, do ECMO and VAD as
reported herein adequately support the patient when
cardiac function is compromised? The answer is clear-
ly yes, although not in every patient, and not indefi-
nitely. Second, does this type of support allow cardiac
improvement to occur if improvement would not other-
wise have occurred in a given patient? This is a much
more complicated question. To ask it another way:
What is the effect of patient selection on outcome? As
in most areas of cardiac surgery, it is profound. As a
group, our VAD patients with anomalous origin of the
left coronary artery from the pulmonary artery and
those with transposition of the great arteries (especial-
ly patients with intact ventricular septum operated on
after 3 weeks of age) had a significantly better survival
probability than others (.91, CL = .59-1.0, P = .04).7
The worst outcome was in patients with technically
imperfect repairs, coagulopathy, and those with com-
plex cardiac anomalies that have an expected poor
long-term outcome even if VAD and ECMO are not
required. Perhaps this type of analysis of indications
begs the question. In practice, if a reliable support
device were available, almost any child accepted for a
cardiac operation would be considered a candidate for
support should the need arise.
Centrifugal-pump VAD is not expensive technology.
In our own unit, an additional nurse is required when
ECMO is used, but not for VAD, during which the
child’s primary nurse also monitors the VAD circuit
(with a perfusionist and cardiac surgeon on call).
Consequently, VAD adds only approximately $250 per
day to normal intensive care unit and hospital expenses,
whereas ECMO adds 4 to 5 times that amount.
The availability of paracorporeal pulsatile devices for
support of infants and children may render the cen-
trifugal pump system obsolete. Certainly there are sev-
eral very elegant systems in use in Europe at this time
that are proving to be suitable for long-term support,
even in very small infants. However, for short-term
assistance, the costs involved may place these devices
out of the reach of many units, especially those not
actively involved in cardiac transplantation.
The results with short-term mechanical support in
Boston, Melbourne, and elsewhere strongly support
continued application of this strategy for selected chil-
dren with severe cardiac failure. The simplicity and
efficacy of centrifugal-pump VAD should place it in the
armamentarium of all units prepared to undertake car-
diac operations in children. In the current era, decre-
ment in surgical mortality is very difficult to come by,
and Duncan and associates have demonstrated a way of
achieving this end.
Tom R. Karl, MS, MD
Victoria, Australia
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